Literature DB >> 31786254

Eosinophilic Asthma.

Ryan K Nelson1, Andrew Bush2, Jeffrey Stokes3, Parameswaran Nair4, Praveen Akuthota5.   

Abstract

Asthma endotypes are constantly evolving. Currently, there are no universally accepted criteria to define endotypes. The TH2-high endotype can have either allergic or nonallergic underpinnings and is typically characterized by some degree of eosinophilic airway inflammation. Unbiased clustering analyses have led to the identification of pediatric and adult phenotypes characterized by TH2 inflammation and associated endotypes with eosinophilic inflammation. Aspirin-exacerbated respiratory disease has also long been recognized as a unique asthma phenotype. An approach to identify these groups with biomarkers and subsequently choose a targeted therapeutic modality, particularly in severe disease requiring biologic agents, is outlined.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspirin-exacerbated respiratory disease; Asthma; Endotypes; Eosinophils

Mesh:

Substances:

Year:  2019        PMID: 31786254     DOI: 10.1016/j.jaip.2019.11.024

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  17 in total

1.  Sex Hormones and Lung Inflammation.

Authors:  Jorge Reyes-García; Luis M Montaño; Abril Carbajal-García; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  [Inhibition of the Notch1/Jagged1 pathway promotes homing of bone mesenchymal stem cells to improve asthma in rats].

Authors:  K Wang; H Zhu; L Yang; Q Xu; F Ren; X Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-10-20

Review 3.  Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.

Authors:  Corrado Pelaia; Giulia Pelaia; Claudia Crimi; Angelantonio Maglio; Giuseppe Armentaro; Cecilia Calabrese; Angela Sciacqua; Luca Gallelli; Alessandro Vatrella
Journal:  Vaccines (Basel)       Date:  2022-06-19

4.  Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression.

Authors:  Corrado Pelaia; Claudia Crimi; Alida Benfante; Maria Filomena Caiaffa; Cecilia Calabrese; Giovanna Elisiana Carpagnano; Domenico Ciotta; Maria D'Amato; Luigi Macchia; Santi Nolasco; Girolamo Pelaia; Simona Pellegrino; Nicola Scichilone; Giulia Scioscia; Giuseppe Spadaro; Giuseppe Valenti; Alessandro Vatrella; Nunzio Crimi
Journal:  J Asthma Allergy       Date:  2021-02-22

Review 5.  Molecular Targets for Biological Therapies of Severe Asthma.

Authors:  Corrado Pelaia; Claudia Crimi; Alessandro Vatrella; Caterina Tinello; Rosa Terracciano; Girolamo Pelaia
Journal:  Front Immunol       Date:  2020-11-30       Impact factor: 7.561

Review 6.  Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies.

Authors:  Corrado Pelaia; Alessandro Vatrella; Luca Gallelli; Nicola Lombardo; Angela Sciacqua; Rocco Savino; Girolamo Pelaia
Journal:  Drug Des Devel Ther       Date:  2021-03-23       Impact factor: 4.162

Review 7.  Asthma and COVID-19: a dangerous liaison?

Authors:  Carlo Lombardi; Federica Gani; Alvise Berti; Pasquale Comberiati; Diego Peroni; Marcello Cottini
Journal:  Asthma Res Pract       Date:  2021-07-15

Review 8.  Pulmonary Surfactants: a New Therapeutic Target in Asthma.

Authors:  Youngwoo Choi; Jaehyuk Jang; Hae-Sim Park
Journal:  Curr Allergy Asthma Rep       Date:  2020-09-11       Impact factor: 4.806

Review 9.  Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologicals in Severe Asthma.

Authors:  Martin Runnstrom; Hilary Pitner; Jennifer Xu; F Eun-Hyung Lee; Merin Kuruvilla
Journal:  J Inflamm Res       Date:  2022-01-11

10.  Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study.

Authors:  Trung N Tran; Marjan Kerkhof; Victoria Carter; David B Price
Journal:  J Asthma Allergy       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.